Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 17;131(10):e149948.
doi: 10.1172/JCI149948.

Innovations in MD-only physician-scientist training: experiences from the Burroughs Wellcome Fund physician-scientist institutional award initiative

Allison T McElvaine  1 , Jacqueline A Hawkins-Salsbury  2 , Vineet M Arora  3 , Mark T Gladwin  4 , James R Goldenring  5 , David P Huston  6 , Deborah Krakow  7 , Kyu Rhee  8 , Julian Solway  3   9 , Richard A Steinman  4 , Dwight A Towler  10 , Paul J Utz  11 , Wayne M Yokoyama  2   12 , Rolly L Simpson  13 , Louis J Muglia  13 , Sallie R Permar  14 , Rasheed A Gbadegesin  1   15
Affiliations

Innovations in MD-only physician-scientist training: experiences from the Burroughs Wellcome Fund physician-scientist institutional award initiative

Allison T McElvaine et al. J Clin Invest. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: VMA reports spouse stock ownership in Acadia Pharmaceuticals. MTG receives research support from Globin Solutions, Inc., the Institute for Transfusion Medicine, and the Hemophilia Center of Western Pennsylvania; is coinventor on patents and patent applications directed to the use of recombinant neuroglobin and heme-based molecules as antidotes for CO poisoning (61/187,527; 9,114,109; 14/776,363; 15/313,231; 62/525,909), which have been licensed by Globin Solutions, Inc.; is a shareholder, advisor, and director in Globin Solutions, Inc.; is coinventor on patents directed to the use of nitrite salts in cardiovascular diseases filed as international application numbers PCT/US2004/022232 (published as WO 2005/004884) and PCT/US2004/021985 (published as WO 2005/007173); and US 10/563,683 and US 12/748,184, which were previously licensed to United Therapeutics and are now licensed to Globin Solutions and Hope Pharmaceuticals; is a principal investigator in a research collaboration with Bayer Pharmaceuticals to evaluate riociguat as a treatment for patients with sickle cell disease; is serving or has served as a scientific consultant for Actelion, Pfizer, Bayer Healthcare, Fulcrum, and Novartis; previously served as a consultant for Acceleron Pharma, Inc., Sujana Biotech, Epizyme, Inc., Catalyst Biosciences, Inc., Complexa, United Therapeutics, and Modus Therapeutics; and is on Bayer HealthCare LLC’s Heart and Vascular Disease Research Advisory Board. DPH holds patents nos. 5,976,821 and 6,395,274 (Anti-Thioredoxin Monoclonal Antibodies) licensed to Genetics Institute (1995), Invitrogen Corp. (1995), Santa Cruz Biotechnology, Inc. (2000); and US patent application nos. 16/348,829 and 16/348,829. JS has interest in PulmOne Advanced Medical Diagnostics, Ltd, Israel, and is inventor on two patents pending (PCT/US20/26371 submitted to USPTO April 2, 2020 and PCT/US20/26383 submitted to USPTO April 2, 2020). SRP has sponsored research agreements with and consults for Merck and Moderna. RLS is Senior Program Officer at the Burroughs Wellcome Fund. LJM is President and CEO at the Burroughs Wellcome Fund.

Figures

Figure 1
Figure 1. PSIA-funded programs, approaches, and career stage targets.
PSIA institutions completed a survey to catalog and compare categorical key approaches across institutions as well as the targeted career stage by program. Key approaches were categorized and approaches newly launched with the PSIA are indicated with black-filled circles. Those that were preexisting at an awardee institution, but incorporated into the PSIA program, are indicated with gray-filled circles. Approaches that were preexisting and not incorporated into the PSIA program are indicated with open circles. Career stage targets by program are indicated with blue-filled circles.
See this image and copyright information in PMC

References

    1. Khot S, et al. The Vietnam war and medical research: untold legacy of the U.S. doctor draft and the NIH “Yellow Berets”. Acad Med. 2011;86(4):502–508. doi: 10.1097/ACM.0b013e31820f1ed7. - DOI - PubMed
    1. Park BS. The development of the intramural research program at the National Institutes of Health after World War II. Perspect Biol Med. 2003;46(3):383–402. doi: 10.1353/pbm.2003.0042. - DOI - PubMed
    1. Appointment of associateships for 1967 at the National Institutes of Health. Public Health Rep. 1965; 80(4):370–371. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1919641/pdf/pubhealthrepori....
    1. Harding CV, et al. History and outcomes of 50 years of physician-scientist training in medical scientist training programs. Acad Med. 2017;92(10):1390–1398. doi: 10.1097/ACM.0000000000001779. - DOI - PMC - PubMed
    1. National Science Foundation. 2016 Doctorate Recipients from US Universities. https://www.nsf.gov/statistics/2018/nsf18304/static/report/nsf18304-repo... Accessed March 30, 2021.